Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can smarter antibiotic use curb Drug-Resistant infections?

NCT ID NCT07082465

Knowledge-focused Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This study looks back at medical records from four hospitals in Thailand to understand what happens when doctors reduce antibiotic treatment (de-escalation) in patients who received short-course IV antibiotics. It compares outcomes like new resistant infections and death between those who had de-escalation and those who didn't. The study also tests automated outbreak detection and develops new stewardship indicators for low- and middle-income countries.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
This could help hospitals in low- and middle-income countries improve antibiotic use and reduce drug-resistant infections.
What could go wrong
Because it's observational, it can't prove cause and effect. Results may not apply to other settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 108,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients admitted to four collaborating hospitals from 1 Jan 2019 to 31 Dec 2024. We expect that the total sample size would be about 108,000 inpatients

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

For primary objectives Inclusion Criteria * All age and gender * Admitted to four collaborating hospitals from 1 Jan 2019 to 31 Dec 2024 * Received a parenteral antibiotic for at least four consecutive days * Were still hospitalized on day 8 after starting a parenteral antibiotic Exclusion Criteria * Admitted as day admissions to four collaborating hospitals from 1 Jan 2019 to 31 Dec 2024 * Had a clinical specimen collected within 2 calendar days of starting a parenteral antibiotic culture positive for an antimicrobial-resistant organism or Staphylococcus aureus Antimicrobial-resistant (AMR) organism is defined as an organism that is resistant to Access and Low Watch antibiotics, and if the organism is the cause of infection, the recommended antimicrobial therapy involves the use of Medium Watch, High Watch or Reserve antibiotics. The common organisms include methicillin-resistant S. aureus, methicillin-resistant coagulase-negative Staphylococcus spp., ampicillin-resistant Enterococcus spp., vancomycin-resistant Enterococcus spp., 3rd-generation cephalosporin-resistant Gram-negative bacterium and carbapenem-resistant Gram-negative bacterium. The definition of organism includes organisms frequently associated with contamination including coagulase-negative staphylococci, viridans group streptococci, Corynebacterium spp., Bacillus spp., Diptheroid spp., Micrococcus spp. and Propionibacterium spp.. All types of specimens are included (e.g. sputum and tracheal suction). We excluded such patients because the study has no clinical data to differentiate whether the isolated AMR organisms are causing infections or represent colonization. For secondary objectives Inclusion Criteria: * All age and gender * Admitted to four collaborating hospitals from 1 Jan 2019 to 31 Dec 2024 Exclusion Criteria: • Admitted as day admissions to four collaborating hospitals from 1 Jan 2019 to 31 Dec 2024

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bacteremia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial infectious disease bacterial infectious disease with sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bacteremia Bacterial Drug resistance

Contacts and locations

Locations

  • Chaoprayayommarat Hospital

    Suphan Buri, Thailand

  • Chiangrai Prachanukroh Hospital

    Chiang Rai, Chiangrai, Thailand

  • Phrachomklao Hospital

    Phetchaburi, Thailand

  • Sunpasitthiprasong Hospital

    Ubon Ratchathani, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.